Toggle Main Menu Toggle Search

Open Access padlockePrints

Cardiovascular Risk Factors in Women With Primary Sjögren's Syndrome: United Kingdom Primary Sjögren's Syndrome Registry Results

Lookup NU author(s): Sheryl Mitchell, Dr Bridget Griffiths, Professor Fai NgORCiD



This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Objective: To compare the performance of the Psoriatic Arthritis Disease Activity Score (PASDAS), the Arithmetic Mean of the Desirability Function (AMDF), the Composite Psoriatic Disease Activity Index (CPDAI), and the Disease Activity Index for Psoriatic Arthritis (DAPSA) in the GO-REVEAL data set. The Disease Activity Score using 28 joints (DAS28) was used as a comparator. Methods: The GO-REVEAL study did not allow full computation of all the composite scores (a modified version of CPDAI was used). The performance of the scores at baseline and followup (weeks 14 and 24) was compared using effect sizes. Results: All indices could distinguish response to treatment at 14 and 24 weeks. Effect sizes at 24 weeks for the 50 mg (100 mg) golimumab doses were 2.18 (2.36), 2.08 (2.36), 1.09 (1.41), 1.80 (1.78), and 1.13 (1.18) for PASDAS, AMDF, modified CPDAI, DAS28, and DAPSA, respectively. Comparison of 24-week values across the 3 treatment groups (placebo, golimumab 50 mg, and golimumab 100 mg) by an analysis of covariance using the baseline values as covariates gave the following F statistics: PASDAS 18.3, AMDF 19.6, modified CPDAI 9.4, DAS28 13.6, and DAPSA 7.9; all of these are highly significant. When the analysis was confined to the 2 golimumab treatment groups, there were no significant between-treatment group differences with any of the composite measures. Conclusion: PASDAS and AMDF were better able to distinguish treatment effect, having larger effect sizes at 24 weeks. PASDAS, AMDF, and modified CPDAI better reflected domains such as skin, enthesitis, and dactylitis.

Publication metadata

Author(s): Juarez M, Toms TE, de Pablo P, Mitchell S, Bowman S, Nightingale P, Price EJ, Griffiths B, Hunter J, Gupta M, Bombardieri M, Sutcliffe N, Pitzalis C, Pease C, Andrews J, Emery P, Regan M, Giles I, Isenberg D, Moots R, Collins KS, Ng WF, Kitas GD, and on behalf of the UK Primary Sjögren's Syndrome Registry

Publication type: Article

Publication status: Published

Journal: Arthritis Care & Research

Year: 2014

Volume: 66

Issue: 5

Pages: 757-764

Print publication date: 22/04/2014

Online publication date: 31/10/2013

Acceptance date: 29/10/2013

Date deposited: 05/08/2015

ISSN (print): 2151-464X

ISSN (electronic): 2151-4658

Publisher: Wiley-Blackwell Publishing Ltd.


DOI: 10.1002/acr.22227


Altmetrics provided by Altmetric


Funder referenceFunder name
Bristol-Myers Squibb
British Sjogren's Syndrome Association
E. Lilly
Newcastle University
G0800629Medical Research Council